<DOC>
	<DOCNO>NCT00144703</DOCNO>
	<brief_summary>The purpose study evaluate ability sirolimus prevent graft versus host disease ( GVHD ) patient follow stem cell transplant relate donor .</brief_summary>
	<brief_title>Sirolimus With Tacrolimus Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation</brief_title>
	<detailed_description>- Therapy prevent GVHD consist infusion tacrolimus intravenously sirolimus orally per day start 3 day stem cell infusion . This take place hospital patient remain duration transplant . - Sirolimus continue 9 week stable dose , taper 1/3 week 9 1/3 week 17 . It stop week 26 significant evidence GVHD . These dose modification occur home patient see weekly first 2 month discharge . - If GVHD present , taper schedule wil slower base upon patient 's clinical condition . - Tacrolimus give orally patient discharge hospital taper schedule sirolimus . Blood level tacrolimus sirolimus monitor dose adjust accordingly . - During year follow stem cell transplant , blood work perform evaluate immune system GVHD .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients hematologic malignancy undergo allogeneic HSCT match familymembers . Age great 18 ECOG performance status 02 Total bilirubin &lt; 2.0 mg/dl AST &lt; 90 IU Serum creatinine &lt; 2.0 mg/dl Active , uncontrolled infection Ejection fraction &lt; 45 % echocardiogram MUGA scan Forced vital capacity &lt; 60 % Uncontrolled hypertension Second transplantation Evidence HIV infection Cholesterol &gt; 300 mg/dl Relapsed aggressive Burkitt 's Burkitt'slike lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Graft versus host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>sirolimus</keyword>
	<keyword>tacrolimus</keyword>
</DOC>